RINVOQ 15 mg tabletten met verlengde afgifte
As listed in the register: RINVOQ 15 mg tabletten met verlengde afgifte
15 mg · tablet met verlengde afgifte
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Upadacitinib 0,5-Water
- Made by
- AbbVie Deutschland GmbH & Co. KG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
Spain1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | AbbVie Deutschland GmbH & Co. KG |
|---|---|
| Active substance | Upadacitinib 0,5-Water |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 15 mg |
| Form | tablet met verlengde afgifte |
| Classification | L04AF03 · Cancer treatments and immune-system medicines |
| Route | oraal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| RVG | EU/1/19/1404 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.